AUSTIN, TX and TORONTO, ON, Feb.

AUSTIN, TEXAS, May 2 /PRNewswire/ - Affinium Pharmaceuticals announced today the results of a new multiple ascending dose Phase I study of its novel, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation. The study examined the tolerability, safety and pharmacokinetics of immediate release tablets of AFN-1252.

AUSTIN, March 15 /PRNewswire/ - Affinium Pharmaceuticals, a clinical-stage drug development company with a novel, specific-spectrum anti-staphylococcal antibiotic, announced today that Dr. Barry Hafkin, Chief Medical Officer, and Dr.

Affinium Pharmaceuticals has started the dosing of healthy subjects in a Phase I study of AFN-1252, one of its lead clinical candidates from its novel class of fatty acid biosyntheis inhibitors.

AUSTIN, TX and TORONTO, March 4 /PRNewswire/ -- Affinium Pharmaceuticals today announced that they have commenced the dosing of healthy subjects in a Phase I study of AFN-1252, one of its lead clinical candidates from its novel class of fatty acid biosyntheis inhibitors.